OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 DeLLphi-304 Trial

@charlesrudin
@g_mountzios
@cbcbc1971
@JulienMazieres
@teekayowo
@LuisPaz_Ares

🫁 Phase 3 (n=509): tarlatamab vs chemotherapy (topotecan, lurbinectedin or amrubicin) in SCLC after first-line platinum-based chemotherapy. Primary endpoint: OS; median follow-up 23 mo.
➡️ Median OS 13.6 vs 8.4 mo; HR 0.62 (0.51–0.76); 18-mo OS 42% vs 24%
➡️ Baseline brain metastases subgroup: OS HR 0.52 (0.38–0.70)
➡️ Grade ≥3 TRAEs 28% vs 63%
✅ Durable survival benefit with a manageable safety profile and no new safety signals, reinforcing tarlatamab as standard of care after first-line platinum-based chemotherapy. #LungCancer #SCLC

🎙️ Charles Rudin
👥 Giannis Mountzios · Longhua Sun · Byoung Chul Cho · Umut Demirci · Sofia Baka · Mahmut Gümüş · Antonio Lugini · Bo Zhu · Yan Yu · Ippokratis Korantzis · Ji-Youn Han · Tudor-Eliade Ciuleanu · Myung-Ju Ahn · Pedro Rocha · Julien Mazières · Sally Lau · Martin Schuler · Fiona Blackhall · Tatsuya Yoshida · Taofeek Owonikoko · Luis Paz-Ares · Tony Jiang · Ali Hamidi · Diana Gauto · Gonzalo Recondo

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD

@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers